FY2024 EPS Estimates for OptiNose Increased by HC Wainwright

OptiNose, Inc. (NASDAQ:OPTN) – Equities research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of OptiNose in a research note issued on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.18) for the year, up from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for OptiNose’s FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.35 EPS.

Separately, Piper Sandler reduced their price objective on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating for the company in a report on Wednesday.

OptiNose Trading Down 4.4 %

OPTN opened at $0.44 on Friday. OptiNose has a twelve month low of $0.41 and a twelve month high of $2.10. The stock has a market cap of $65.61 million, a PE ratio of -1.55 and a beta of -0.07. The business’s 50 day moving average is $0.74 and its 200-day moving average is $0.95.

Hedge Funds Weigh In On OptiNose

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of OptiNose in the second quarter worth approximately $88,000. GSA Capital Partners LLP acquired a new position in OptiNose during the third quarter valued at $61,000. Squarepoint Ops LLC boosted its position in OptiNose by 173.7% during the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after acquiring an additional 108,903 shares during the period. Oracle Investment Management Inc. acquired a new position in shares of OptiNose in the 1st quarter valued at about $474,000. Finally, State Street Corp increased its stake in OptiNose by 14.2% in the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after buying an additional 42,500 shares during the period. Institutional investors and hedge funds own 85.60% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.